Viewpoint: Should doctors talk with their patients about the politics roiling medicine? Some say it’s their responsibility. MedPage Today | October 30, 2026

https://geneticliteracyproject.org/2026/10/30/viewpoint-should-doctors-talk-with-their-patients-about-the-politics-roiling-medicine-some-say-its-their-responsibility/ Doctors are supposed to tell patients when they find a worrisome tumor. According to Harvard Medical School professor Jerry Avorn, they should also tell patients when Washington is about to cut off their healthcare. In a recent op-ed for MedPage Today, Avorn argues that with deep Medicaid cuts on the way, the old taboo against talking politics in the exam room has to go.

‘Warp-speeding this treatment’: Trump’s VA readies psychedelic therapy for up to 2 million veterans Politico | October 30, 2026

https://geneticliteracyproject.org/2026/10/30/warp-speeding-this-treatment-trumps-va-readies-psychedelic-therapy-for-up-to-2-million-veterans/ The Veterans Health Administration wants to be ready to offer psychedelics like psilocybin and MDMA to as many as 2.1 million veterans with PTSD or depression — even though no regulator has yet deemed the drugs safe or effective for mental illness, as Politico’s Amanda Friedman reports. Andrew Gradison, a senior adviser at the VA, laid out that ambition at the Horizons: Perspectives on Psychedelics conference in New York. Reality will lag behind, he admitted: “Our demand will exceed our ability to supply these therapies, no doubt.” Even treating “four digits worth of patients” in the first year after an FDA approval will be a challenge.

RFK Jr. blames RSV on a chimpanzee lab leak: Dissecting false claims about the respiratory virus’s origins The Atlantic | October 30, 2026

https://geneticliteracyproject.org/2026/10/30/rfk-jr-blames-rsv-on-a-chimpanzee-lab-leak-dissecting-false-claims-about-the-respiratory-viruss-origins/ Health Secretary Robert F. Kennedy Jr. keeps insisting that RSV — respiratory syncytial virus, which puts more U.S. babies in the hospital than any other virus — escaped from a lab. It didn’t, and as The Atlantic’s Tom Bartlett reports, the historical record isn’t remotely ambiguous on the point.

A precision T-cell therapy stalls treatment-resistant cancers in clinical trial Experimental drug invika halts progression of refractory tumors by selectively stimulating tumor-fighting T cells.

https://www.nih.gov/news-events/news-releases/precision-t-cell-therapy-stalls-treatment-resistant-cancers-clinical-trial U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH NIH News National Institutes of Health For Immediate Release: Friday, October 23, 2026 CONTACT: NIH Office of Communications, A PRECISION T-CELL THERAPY STALLS TREATMENT-RESISTANT CANCERS IN CLINICAL TRIAL Experimental drug invika halts progression of refractory tumors by selectively stimulating tumor-fighting T cells Early results of the first clinical trial to evaluate the drug invikafusp alfa (invika) in humans indicate that the pioneering treatment may be capable of managing cancers that have rebuffed most other interventions, including standard immunotherapy. A study led by researchers at the National Institutes of Health (NIH), Mass General Brigham and Memorial Sloan Kettering found that, at optimal doses, invika was well tolerated and, in patients whose solid tumors had resisted standard immunotherapy, halted disease progression in most and shrank tumors in some. “Patients whose tumors are advanced — particularly tumors that don’t respond well to immunotherapy — often have their backs against a wall. Few options remain once you reach that point, but these results highlight a more precise means of stimulating anti-tumor immunity that could provide another solution,” said co-corresponding author James Gulley, M.D., Ph.D., clinical director at the Center for Cancer Research (CCR), part of NIH’s National Cancer Institute (NCI). While immunotherapies have already transformed treatment for several cancers, many patients benefit from them for only a short time, or not at all. Tumors frequently adapt to immune checkpoint blockade (ICB) therapies, such as pembrolizumab, limiting long-term benefits. Other strategies aim to rally T cells, the frontline soldiers of adaptive immunity, but usually do so indiscriminately, commonly leading to severe side effects. Scientists designed the protein invika to engage a small subset of T cells, two groups of tumor-infiltrating lymphocytes specifically. By activating only this narrow population rather than T cells broadly, invika is designed to drive anti-tumor activity while avoiding the severe side effects that less selective approaches can cause. Preclinical studies also conducted at CCR indicate that the drug hits its intended marks and stimulates anti-tumor activity in animal models . This new study describes the next step for invika, detailing the results of phase 1 and initial phase 2 experiments in humans. The researchers leading the trial recruited patients with a wide variety of cancers, the majority of which had not responded well to ICB. In phase 1, they treated study participants with varying dosages of invika every two weeks to evaluate the drug’s safety and determine the optimal dose. While several participants experienced flu-like side effects, these were expected and generally manageable with additional medication and supportive care. After identifying the lowest dose at which desired effects peaked, the researchers advanced to phase 2, treating participants at this optimal dose. Of the 27 participants treated with the optimal dose across both phases, disease did not progress in 16 (59.3%) of them. Four (14.8%) participants experienced greater than 30% decreases in the size of targeted tumors, two of whom had metastatic colorectal cancer with tumors of a notoriously treatment-resistant type and were receiving invika as their seventh-line therapy. Another responsive participant had stage 4 non-small cell lung cancer, again with tumors that had repelled multiple therapies including ICB. In participants receiving non-optimal levels, invika did not appear to have significant benefit. In these patients, the study authors found that the drug fostered growth in the target T-cell populations without affecting any other T cells. They linked the four instances of tumor reduction to the largest shifts in target populations, though, as the authors expected at this early stage, immune activity alone did not always produce a measurable clinical response. “These results are early, and although signs of immune activity don't always translate into benefit to patients at this stage, it is new and exciting to see activity in patients whose cancers had stopped responding to immunotherapy — a group of people with very few options left,” said co-first author Nicholas Tschernia, M.D., a physician-scientist early investigator in the CCR at NCI. “These findings give us a reason to keep studying this new type of immunotherapy, particularly by combining it with other cancer treatments to continue to seek improved results.” The treatment sponsor, Marengo Therapeutics, previously announced that the U.S. Food and Drug Administration (FDA) granted a Fast Track designation to invika to accelerate its evaluation as a treatment for antigen-rich, metastatic colorectal cancer. More recently, FDA has granted the same designation to invika for similar solid tumors, regardless of tissue type, following prior therapy including checkpoint inhibitors. The ongoing clinical trial is still seeking study participants. Patients interested in enrolling in this study may contact NCI’s toll-free number 1-800-4-Cancer (1-800-422-6237) (TTY: 1-800-332-8615) or email NCIMO_referrals@mail.nih.gov. More information can also be found at . About the National Cancer Institute (NCI): NCI leads the National Cancer Program and NIH’s efforts to dramatically reduce the prevalence of cancer and improve the lives of cancer patients and their families, through research into prevention and cancer biology, the development of new interventions, and the training and mentoring of new researchers. NCI’s intramural research program at the Center for Cancer Research (CCR) conducts innovative, transdisciplinary basic, translational, and clinical studies, including research at the NIH Clinical Center — the world’s largest research hospital. Learn more about the intramural research done in NCI’s CCR. For more information about cancer, please visit the NCI website at www.cancer.gov or call NCI’s contact center, the Cancer Information Service, at 1-800-4-CANCER (1-800-422-6237). About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov. NIH...Turning Discovery into Health -- Registered, U.S. Patent and Trademark Office --- REFERENCE: Ryan J. Sullivan, Nicholas P. Tschernia, Claire F. Friedman et al. Bispecific dual T cell agonist invikafusp alfa in solid tumors: the phase 1/2 START-001 trial. Nature Medicine. October 23, 2026. DOI: 10.1038/s41591-026-04711-0 ### This NIH News Release is available online at:

Reshaping Gastroesophageal Adenocarcinoma Care: Integrating New Anti-HER2 Therapies CME/CNE/CPE/IPCE Monday, November 9, 2026 | 3:30 pm - 4:15 pm ET

https://na.eventscloud.com/website/99132/ Transform your gastroesophageal adenocarcinoma (GEA) practice by joining expert oncologists Elena Elimova, Samuel J. Klempner, and Kohei Shitara for an interactive, 45-minute online discussion. Unpack the latest clinical trial data for novel anti-human epidermal growth factor receptor 2 (HER2) regimens, learn how to integrate new frontline regimens into care for patients with HER2-positive GEA, and gain insight into postprogression strategies. Faculty will also discuss proactive team-based approaches to toxicity management. Register now to elevate your clinical decision-making.

The Fifth Transatlantic Exchange in Oncology: Transatlantic Innovations in Cancer Drug Research – A Selection of Key Presentations From the Event

https://www.medscape.com/medicalaffairs/448002.4/media-6?src=0_nl_sm_0&uac=148436CN The Fifth Annual Transatlantic Exchange in Oncology reflects an ongoing collaboration between key scientists, clinicians, and researchers from the Institut Gustave Roussy in Villejuif, France and Dana-Farber Cancer Institute (DFCI) in Boston, USA (supported by L’Institut Servier). This year’s event brought together a global audience with expertise in medical oncology, translational research, and molecular biology to exchange and discuss insights and new developments in the rapidly evolving area of cancer drug research. The event was held in Boston – at the Jimmy Fund Auditorium at DFCI - on March 27, 2026. Prof Eric Fischer from DFCI gave his insights on the day with this short “Expert Commentary” on the program. Prof Toni Choueiri then provides the Welcome Address. This is followed by 4 videos from the day’s events which reflect the depth and diversity of cancer drug research and collaboration across the Atlantic. Dr François-Xavier Danlos (Institute Gustave Roussy) explores data from the PREMIS study to show how genetic backgrounds may influence the susceptibility of patients to immune-related adverse events (irAE).

American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting (+...)

https://www.medscape.com/c25/p14/american-college-gastroenterology-acg-2026-annual-scientific-2026a1000zqb?ecd=wnl_conf_gastro_ACG_SPON_261030_mscpedit_etid8845938&uac=148436CN&impID=8845938

American College of Chest Physicians (CHEST) 2026 Annual Meeting (+...)

https://www.medscape.com/c25/p14/american-college-chest-physicians-chest-2026-annual-meeting-2026a1000zqc?ecd=wnl_conf_pulm_CHEST_SPON_261031_mscpedit_etid8848949&uac=148436CN&impID=8848949

Editorial e829 CAR T cells in autoimmunity: safety first The Lancet Rheumatology

Editorial e829 CAR T cells in autoimmunity: safety first The Lancet Rheumatology https://www.thelancet.com/issue/S2665-9913(26)X2010-0

Editorial e847 Perinatal mental health care must reach women before crisis The Lancet Obstetrics, Gynaecology, & Women's Health (+...)

Editorial e847 Perinatal mental health care must reach women before crisis The Lancet Obstetrics, Gynaecology, & Women's Health https://www.thelancet.com/issue/S3050-5038(26)X2009-X

Navigating the Data: Patient Eligibility for Novel Oral Therapies in EBC Authors: Aditya Bardia, MD, MPH, FASCO; Sara Hurvitz, MD, FACP; Miguel Martin, MD, PhD

https://www.medscape.org/viewarticle/navigating-data-patient-eligibility-novel-oral-therapies-ebc-2026a10014e1?page=1

Thalassaemia revisited: whose progress? The Lancet Haematology (+...)

Thalassaemia revisited: whose progress? The Lancet Haematology https://www.thelancet.com/journals/lanhae/issue/vol13no11/PIIS2352-3026(26)X2010-5

Voices in Care: Multidisciplinary and Patient Perspectives on Advanced/Recurrent Endometrial Cancer Authors: Eva-Maria Strömsholm; Rebecca Kristeleit, MBChB, MRCP, PhD; Domenica Lorusso, MD, PhD; Antonio González-Martín, MD, PhD; Claire Lusted, ANP

https://www.medscape.org/viewarticle/voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui?page=1&src=mkmcmr_driv_stan_mscpedu_261030-OUS-HONC-voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui-cta&uac=148436CN

Generalized Myasthenia Gravis: AANEM 2026 Highlights

Generalized Myasthenia Gravis: AANEM 2026 Highlights Key data updates, therapeutic strategies, and evolving standards of care in generalized myasthenia gravis The American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) held its 2026 annual meeting September 29–October 1 in Orlando. CheckRare focused its meeting coverage on generalized myathesthenia gravis (gMG), and its treatment and management. https://checkrare.com/generalized-myasthenia-gravis-aanem-2026-highlights/

Chronic Lymphocytic Leukemia: Data-Driven Updates in First-Line and R/R Disease Authors: Barbara F. Eichhorst, MD; Toby A. Eyre, MD, MBChB, DipMedEd, MRCP, FRCPath; Catherine Coombs, MD; Chan Cheah, MBBS, DMSc

https://www.medscape.org/viewarticle/chronic-lymphocytic-leukemia-data-driven-updates-first-line-2026a1000imb?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261030-OUS-HONC-chronic-lymphocytic-leukemia-data-driven-updates-first-line-2026a1000imb-cta

Fever Blisters & Canker Sores

https://www.nidcr.nih.gov/health-info/fever-blisters-canker-sores

FDA Approves First Plasmid DNA-based Immunotherapy for Adults with Recurrent Respiratory Papillomatosis

https://www.fda.gov/news-events/press-announcements/fda-approves-first-plasmid-dna-based-immunotherapy-adults-recurrent-respiratory-papillomatosis?utm_medium=email&utm_source=govdelivery The U.S. Food and Drug Administration today granted accelerated approval for Voceryq (doruxapapogene ralaplasmid and lalikinogene sifuplasmid-gxfd) for treatment of adults with recurrent respiratory papillomatosis (RRP), a rare disease caused by human papillomavirus (HPV) that leads to the formation of small, wart-like growths in the patient’s airways. This approval, the first for a plasmid DNA-based immunotherapy in the U.S., offers patients a new therapeutic option that targets the root cause of RRP and has been shown to reduce the burden of surgical intervention, representing an important step forward for a patient population with limited treatment options. “Adults living with recurrent respiratory papillomatosis often face an exhausting and relentless cycle of repeated surgeries, managing their disease, but never truly escaping it. Today’s approval represents a meaningful scientific breakthrough: a plasmid DNA-based immunotherapy that harnesses the body’s own immune system to fight the underlying cause of RRP,” said Karim Mikhail, B. Pharm., M.S., Director of the Center for Biologics Evaluation and Research (CBER). “For patients, that could mean fewer surgeries, fewer disruptions, and more time living their lives on their own terms. The FDA is proud to help bring that possibility within reach.”

Dissecting the Evidence: Interpreting Recent Clinical Trial Data for Radiopharmaceutical-Based Combinations in Metastatic Castration-Resistant Prostate Cancer Authors: Bertrand Tombal, MD, PhD; Alicia K. Morgans, MD, MPH, FASCO

https://www.medscape.org/viewarticle/dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un?page=1&src=mkmcmr_driv_stan_mscpedu_261030-OUS-HONC-dissecting-evidence-interpreting-recent-clinical-trial-data-2026a10009un-cta&uac=148436CN

An RNA splicing factor could help reverse cellular aging A machine learning-based screen identified SRSF1 as a potential target for reversing several hallmarks of aging without erasing cell identity, with further testing revealing benefits in aged mice. Written byBree Foster, PhD

An RNA splicing factor could help reverse cellular aging A machine learning-based screen identified SRSF1 as a potential target for reversing several hallmarks of aging without erasing cell identity, with further testing revealing benefits in aged mice. Written byBree Foster, PhD https://www.drugdiscoverynews.com/an-rna-splicing-factor-could-help-reverse-cellular-aging-17593?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz--q0TCL9BRDIVwGZzG8D-aIKlFudGIjubKRKoEWvi9yeaf8px0uyH3QUEU036cvr7HW-2_0UwJ9sHaPnQ-6C5QFT4TM5w&_hsmi=446568641&utm_content=446568641&utm_source=hs_email Aging gradually erodes the function of cells, tissues, and organs, increasing the risk of chronic diseases such as cardiovascular disease, neurodegeneration, and cancer. Researchers are therefore investigating ways to reverse age-related changes without disrupting normal cellular function. RNA therapeutics grow up as manufacturing catches up Beyond mRNA vaccines, siRNA and antisense therapies are advancing as chemistry, AI, and manufacturing finally keep pace with clinical ambition. Written byAndrea Corona https://www.drugdiscoverynews.com/rna-therapeutics-grow-up-as-manufacturing-catches-up-17490?utm_campaign=DDN_Newsletter_Dose&utm_medium=email&_hsenc=p2ANqtz-_z9ACx2BDSaavfoYSuWKDPokTb4Eqk0mjOe6vRt_53I5ESPrw6Hn3g3_Yji_lxfQ2S40I9i0WWXrQI1rPSMBCb3vUW1Q&_hsmi=446568641&utm_content=446568641&utm_source=hs_email mRNA vaccines proved RNA-based medicines could work at scale. But RNA therapeutics have moved well beyond that single modality, with siRNA and antisense oligonucleotides (ASOs) now carrying multiple approved products and pipelines expanding into cardiometabolic, central nervous system (CNS), and rare liver diseases. What has changed isn't just the science, according to Jing Zhu, vice president of technical operations and commercial strategy at Hongene Biotech, but manufacturability. "These molecules aren't just scientifically interesting anymore, but they're actually manufacturable at scale, which matters more than people give it credit for," Zhu told DDN, pointing to GalNAc conjugation as a case in point: the approach simplified liver-targeted delivery relative to lipid nanoparticles, streamlining the path from chemistry to manufacturing.

Targeting Plasmodium falciparum pathways to overcome antimalarial resistance Paul C. Chikezie1,2,*ORCID iD , Franklyn O. Ohiagu3ORCID iD , Raphael C. Ekeanyanwu2ORCID iD , Augustine A. Uwakwe4ORCID iD , Chinwendu M. Chikezie5ORCID iD , Muideen R. Gbadamosi1ORCID iD , Ogueri Nwaiwu

https://www.academia.edu/3071-2521/2/3/10.20935/AcadDrug8499 The global burden of malaria remains substantial, exacerbated by the progressive emergence of resistance to frontline antimalarial therapies. Plasmodium falciparum, the most lethal malaria parasite, has developed reduced susceptibility to artemisinin-based combination therapies and several partner drugs, underscoring the urgent need for therapeutics acting on novel molecular targets. This review aims to critically evaluate emerging molecular targets for antimalarial drug development and assess the current preclinical and clinical evidence supporting their therapeutic potential in overcoming drug resistance. Evidence for this study was gathered through extensive searches of major scientific databases (PubMed, EMBASE, ScienceDirect, SpringerLink, and Google Scholar) from 1985 to 2026. A total of 53 references were selected to support the review. Advances in parasite genomics, metabolic profiling, and high-throughput screening have expanded the antimalarial target landscape, revealing essential enzymes, transporters, and regulatory pathways critical for parasite survival across life cycle stages. The review demonstrates that several genetically validated parasite-specific targets, namely Plasmodium falciparum phosphatidylinositol 4-kinase (PfPI4K), the P-type Na+-ATPase (PfATP4), dihydroorotate dehydrogenase (PfDHODH), folate metabolism enzymes, the methylerythritol phosphate (MEP) isoprenoid biosynthesis pathway, and P. falciparum eukaryotic translational elongation factor 2 (PfeEF2), have shown promising preclinical and early clinical efficacy. Collectively, these novel pathways represent promising avenues for next-generation antimalarial drug development and combination therapy strategies. https://www.academia.edu/journals/academia-drug-development-and-pharmacotherapy/articles?source=journal-top-nav

Is AI changing what gives our lives meaning?

https://www.news-medical.net/news/20261029/Is-AI-changing-what-gives-our-lives-meaning.aspx As AI blurs the boundaries between human and machine, researchers examine how emerging technologies challenge our understanding of identity, purpose, and human connection. A new rapid review in the journal Humanities and Social Sciences Communications explores how digital technologies, digital literacy, and knowledge management shape existential inquiry and meaningful engagement with technology.

Multivitamins boost key vitamin levels, but do they improve your health?

https://www.news-medical.net/news/20261029/Multivitamins-boost-key-vitamin-levels-but-do-they-improve-your-health.aspx Millions take multivitamins hoping to protect their health, but what do decades of clinical trials reveal about their effects on memory, pregnancy, heart health, and aging? In a recent review published in the Journal of Dietary Supplements, the researchers examined the efficacy and safety of multivitamin use in adults. The effects varied by supplement formulation, population, and duration of use.

Online reviews reveal troubling side effects of insomnia drug lemborexant

https://www.news-medical.net/news/20261029/Online-reviews-reveal-troubling-side-effects-of-insomnia-drug-lemborexant.aspx Researchers from Rutgers and other universities analyzed hundreds of online reviews on lemborexant – and learned that about 1 in 4 of the reviewers stopped or planned to stop taking the prescription medication used to treat insomnia. Insomnia – difficulty falling or staying asleep – affects about 30% of adults, according to prior sleep research. Lemborexant, approved in the U.S. in 2019, belongs to the newest class of insomnia drugs. Rather than broadly sedating the brain like many older sleeping pills, these medicines block signals from orexin, a chemical messenger that helps keep people awake. In clinical trials, lemborexant (sold as Dayvigo) helped people fall asleep faster and stay asleep longer than a placebo. Ongoing work at Rutgers Brain Health Institute is investigating the potential repurposing of orexin-based sleep medications to treat sleep disturbances in a range of psychiatric conditions, including addiction.

Gut microbial catalog reveals systemic inflammation drivers in spinal injury

https://www.news-medical.net/news/20261030/Gut-microbial-catalog-reveals-systemic-inflammation-drivers-in-spinal-injury.aspx Scientists exploring the links between a spinal cord injury, inflammation and immune function have turned their attention to a genome-level analysis of the gut microbial community, with early study results offering hints at potential new approaches to aid healing.

Tailoring prostate cancer radiotherapy to body clock could cut long-term side effects

https://www.news-medical.net/news/20261030/Tailoring-prostate-cancer-radiotherapy-to-body-clock-could-cut-long-term-side-effects.aspx A study by Leicester researchers shows that the timing of radiotherapy treatment may be as important as how it is given for prostate cancer patients. Researchers at the University of Leicester have discovered that a patient’s genetic makeup and the time of day they receive radiotherapy can work together to influence their risk of developing long-term side effects for treatment of prostate cancer.

Voices in Care: Multidisciplinary and Patient Perspectives on Advanced/Recurrent Endometrial Cancer Authors: Eva-Maria Strömsholm; Rebecca Kristeleit, MBChB, MRCP, PhD; Domenica Lorusso, MD, PhD; Antonio González-Martín, MD, PhD; Claire Lusted, ANP

https://www.medscape.org/viewarticle/voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui?page=1&src=mkmcmr_driv_stan_mscpedu_261026-OUS-HONC-voices-care-multidisciplinary-and-patient-perspectives-2026a1000hui-cta&uac=148436CN

FDA approves talazoparib with enzalutamide for metastatic androgen pathway modulation-naïve or -sensitive prostate cancer with HRR gene mutations

https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-talazoparib-enzalutamide-metastatic-androgen-pathway-modulation-naive-or-sensitive?utm_medium=email&utm_source=govdelivery On October 26, 2026, the Food and Drug Administration (FDA) approved talazoparib (Talzenna, Pfizer Inc.) in combination with enzalutamide for the treatment of adults with metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test.

Improving men's health in a changing world The Lancet (+...)

Improving men's health in a changing world The Lancet https://www.thelancet.com/journals/lancet/issue/vol408no10566/PIIS0140-6736(26)X2041-4

Reviving silent genes to treat Prader-Willi syndrome Researchers tested a new antisense oligonucleotide therapy that turns the maternal healthy genes back on to target the underlying cause of disease. Written byAllison Whitten, PhD

Reviving silent genes to treat Prader-Willi syndrome Researchers tested a new antisense oligonucleotide therapy that turns the maternal healthy genes back on to target the underlying cause of disease. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/reviving-silent-genes-to-treat-prader-willi-syndrome-17615 In Prader-Willi syndrome — a rare genetic disease that leads to physical and metabolic changes and developmental delays — a group of genes on chromosome 15 inherited from the father are not expressed. The child still inherits the healthy versions from the mother, but they remain silent. New research from Marnie Blewitt’s lab at the Walter and Eliza Hall Institute of Medical Research is investigating what happens if the maternal genes are switched back on. In a recent paper published in Science Advances, her team showed that using antisense oligonucleotides in mice and patient-derived neural cells to target the SMCHD1 protein, which is required to keep the maternal genes silenced, successfully restored the silenced gene activity. In mouse models of the condition, this led to improvements in social interaction, physical strength, and reduced weight.

A new strategy targets multiple proteins to restore cell function A new approach to protein degradation improved mitochondrial function and neuronal survival in cell models of several mitochondrial disorders. Written byBree Foster, PhD

A new strategy targets multiple proteins to restore cell function A new approach to protein degradation improved mitochondrial function and neuronal survival in cell models of several mitochondrial disorders. Written byBree Foster, PhD https://www.drugdiscoverynews.com/a-new-strategy-targets-multiple-proteins-to-restore-cell-function-17609 Most drugs are designed to inhibit a particular protein or interfere with its activity. But in diseases involving widespread cellular dysfunction, targeting a single protein may not be enough. What if, instead, researchers could activate the cell’s own machinery to remove several problematic proteins at once? In a study published in Science, researchers describe a strategy called stimulated protein degradation (SPD), which activates a cellular protein-clearance system to accelerate the breakdown of multiple proteins. In cellular models of mitochondrial disorders, the approach improved mitochondrial function and helped neurons survive.

Genmab’s head and neck bispecific cancer drug reduced death by 50 percent FDA guidance, trial results, glioblastoma studies, and more led the news this week. Brought to you byDDN editorial team

Genmab’s head and neck bispecific cancer drug reduced death by 50 percent FDA guidance, trial results, glioblastoma studies, and more led the news this week. Brought to you byDDN editorial team https://www.drugdiscoverynews.com/genmab-s-head-and-neck-bispecific-cancer-drug-reduced-death-by-50-percent-17621 Genmab’s $8 billion acquisition of Merus last year appears to be paying off already. Through that deal, the company gained Merus’ bispecific antibody drug, petosemtamab, that treats head and neck cancer. Phase 3 results announced on Wednesday of this week demonstrated that petosemtamab, in combination with Merck’s Keytruda, decreased the risk of death by 50 percent compared to Keytruda alone in patients with PD-L1 positive head and neck squamous cell carcinoma (HNSCC). The announcement sent Genmab’s stock soaring up nearly 30 percent, and follows two other recent successes from Genmab, with positive results announced earlier this month for epcoritamab in lymphoma and rinatabart sesutecan in ovarian cancer released last week. “These topline Phase 3 results represent a defining milestone for Genmab and further strengthen our conviction in petosemtamab as a potential first-in-class treatment option for patients with this difficult-to-treat cancer,” said Jan van de Winkel, CEO of Genmab, in the press release. – Allison Whitten

Immunotherapy in Locally Advanced Head and Neck Cancer: Evidence, Impact, and Integration Authors: Hisham Mehanna, FMedSci, PhD, BMedSc (hons), MB ChB (hons), FRCS, FRCS (ORL-HNS); Robert Haddad, MD

https://www.medscape.org/viewarticle/immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq?page=1&src=mkmcmr_driv_stan_mscpedu_261029-OUS-HONC-immunotherapy-locally-advanced-head-and-neck-cancer-evidence-2026a1000khq-cta&uac=148436CN

Sonesitatug Vedotin Improves Survival in Gastroesophageal Cancer Tara Haelle

https://www.medscape.com/viewarticle/sonesitatug-vedotin-improves-survival-gastroesophageal-2026a10015cu?src= Patients with previously treated Claudin 18.2-positive advanced or metastatic gastroesophageal carcinoma had longer progression-free and overall survival with the investigational antibody-drug conjugate sonesitatug vedotin than with investigator’s choice of therapy. https://www.medscape.com/c25/p14/european-society-medical-oncology-esmo-annual-meeting-2026-2026a1000zc2

Treatment-Induced Menopause Hikes CVD Risk: What to Know JoAnn E. Manson, MD, DrPH

https://www.medscape.com/viewarticle/treatment-induced-menopause-hikes-cvd-risk-what-know-2026a100144g?ecd=WNL_trdalrt_pos1_ous_261030_etid8848579&uac=148436CN&impID=8848579 Hello. This is Dr JoAnn Manson, professor of medicine at Harvard Medical School and Mass General Brigham. I'd like to talk with you about a recent report on iatrogenic menopause (surgical bilateral oophorectomy or menopause medically induced by chemotherapy or radiation), age at menopause, and risk for cardiovascular morbidity and mortality, just published in JAMA Network Open.

Lessons From the Real World: Treating High Risk HR+/HER2- Breast Cancer According to the Latest Evidence Authors: Nadia Harbeck, MD, PhD; Stephen Johnston, MA, FRCP, PhD; Sara Tolaney, MD, PhD

https://www.medscape.org/viewarticle/lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd?page=1&src=mkmcmr_driv_stan_mscpedu_261030-OUS-HONC-lessons-real-world-treating-high-risk-hr-her2-breast-cancer-2026a1000bhd-cta&uac=148436CN

Clinical Trials for Rare Endocrine Disorders

In this episode, endocrinologist Margarita Ochoa-Maya, MD, speaks with endocrinologist Katherine Arakay, MD, of the University of California, Los Angeles (UCLA), about clinical trials for rare endocrine disorders. The conversation examines clinical trials from three perspectives: patients, clinical researchers, and sponsors.

Clinical Trials in Rare Endocrine Disorders | Rare Endocrine Exchange

In this episode, endocrinologist Margarita Ochoa-Maya, MD, speaks with endocrinologist Katherine Arakay, MD, of the University of California, Los Angeles (UCLA), about clinical trials for rare endocrine disorders. The conversation examines clinical trials from three perspectives: patients, clinical researchers, and sponsors.

Gambling on Clinical Trials

Gambling on Clinical Trials

In this episode, we discuss gambling on clinical trials, the FDA approval of a new formulation of Sjögren’s disease treatment, and an approval in IgA nephropathy. Produced by CheckRare. Explore additional CME activities, physician interviews, podcasts, and rare disease resources at CheckRare.com. Subscribe to the CheckRare Podcast Network for the latest rare disease education, expert interviews, and weekly news. Part of the CheckRare Podcast Network: Trusted conversations, news, education, and expert insights across the rare disease community.

Miv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia Gravis by Chad Birt| Published on: Oct 30, 2026

Miv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia Gravis by Chad Birt| Published on: Oct 30, 2026 Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses one-year data showing sustained benefits of KYV-101 (mivocabtagene autoleucel ; Miv-cel) in stiff person syndrome (SPS), along with longer-term follow-up data in generalized myasthenia gravis (gMG). https://checkrare.com/miv-cel-shows-durable-results-in-stiff-person-syndrome-and-myasthenia-gravis/

We’re likely over-consuming the world’s most profitable nutrient – and it’s wrecking our waistlines. BBC | October 29, 2026

https://geneticliteracyproject.org/2026/10/29/were-likely-over-consuming-the-worlds-most-profitable-nutrient-and-its-wrecking-our-waistlines/ Protein has become the darling of the grocery aisle, stamped on everything from cereal to snack bars. But as BBC Science Focus’s Jessica Bradley reports, most of us already eat more protein than we need — and the surplus is more likely to widen waistlines than build muscle.

Genetics of IQ: At what age do various forms of intelligence peak? Aporia Magazine | October 28, 2026

https://geneticliteracyproject.org/2026/10/28/genetics-of-iq-at-what-age-do-various-forms-of-intelligence-peak/ Bad news for anyone counting on getting sharper with age: once a few statistical quirks are corrected, overall IQ most likely peaks in your thirties, not your seventies. That’s the case Adam Rochussen, a fellow at the Salk Institute for Biological Studies and the Roots of Progress Institute, makes in Aporia Magazine.

Viewpoint: How to rebuild trust in public health in an age of misinformation, political division, and media fragmentation Emily Gaines Buchler | Johns Hopkins University | October 29, 2026

https://geneticliteracyproject.org/2026/10/29/viewpoint-how-to-rebuild-trust-in-public-health-in-an-age-of-misinformation-political-division-and-media-fragmentation/ In the Facebook group Crunchy Moms: Natural Living & Clean Products, a debate rages over childhood vaccines amid posts about breastfeeding and artificial preservatives. One mom gets fed up and announces her departure: “I joined expecting conversations about organic food, holistic tips, and thoughtful ways to support our children—not the promotion of refusing routine childhood vaccinations.”

Viewpoint: AI pioneer Anthropic is going public. Should we embrace its transformative ambitions and safety promises, remain wary—or both? MIT Technology Review | October 29, 2026

https://geneticliteracyproject.org/2026/10/29/viewpoint-ai-pioneer-anthropic-is-going-public-should-we-embrace-its-transformative-ambitions-and-safety-promises-remain-wary-or-both/ Anthropic has filed to go public, and its IPO paperwork reads less like a sales pitch than a warning label. As MIT Technology Review’s Will Douglas Heaven reports, roughly 100 pages of the company’s 335-page IPO prospectus filed with the SEC focus on risks, including the chance its AI could “pose catastrophic or existential risks to humanity.”

Viewpoint: RFK Jr. gives MAHA health grifters a green light to sell six peptides the FDA previously removed over safety concerns Ars Technica | October 29, 2026

https://geneticliteracyproject.org/2026/10/29/viewpoint-rfk-jr-gives-maha-health-grifters-a-green-light-to-sell-six-peptides-the-fda-previously-removed-over-safety-concerns/ Robert F. Kennedy Jr. has overruled his own agency’s scientists, issuing a rule that lets compounding pharmacies make and sell six peptide drugs the FDA pulled from its approved list in 2023 over safety concerns, as Beth Mole for Ars Technica reports. The peptides — BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500 — are hugely popular in the Make America Healthy Again movement, and several prominent MAHA figures sell them.

Viewpoint: How badly is the U.S. food-safety net fraying? FDA’s bungled handling of the tainted lettuce crisis deepens concerns over cuts to disease tracking and response Henry Miller, Jon Entine | October 27, 2026

https://geneticliteracyproject.org/2026/10/27/viewpoint-how-badly-is-the-u-s-food-safety-net-fraying-the-fdas-bungled-handling-of-the-summers-tainted-lettuce-crisis-deepens-concerns-over-administration-cuts-to-disease-trackin/ This summer, a Cyclospora outbreak linked to iceberg lettuce sickened almost 13,000 people in 21 states, killing two. Investigators traced the illnesses to lettuce supplied by Taylor Farms de Mexico, but the FDA closed its investigation on October 2 without determining how the food became contaminated, leaving questions about how to prevent similar outbreaks in the future.

Race against food rot: How AI and gene editing could slash fruit and vegetable waste Juliet Wilcox | October 28, 2026

https://geneticliteracyproject.org/2026/10/28/race-against-food-rot-how-ai-and-gene-editing-could-slash-fruit-and-vegetable-waste/ Every year, between a quarter and half of all the fruits and vegetables grown on Earth never reach a hungry mouth. They rot in transit, succumb to fungal disease, or simply age past the point of sale, wasting billions of dollars along with the water, land, labor and energy that went into producing them. A sweeping new review published in Current Research in Food Science argues that this chronic hemorrhage of food is finally meeting its match, as artificial intelligence and modern biotechnology converge to transform postharvest handling from a reactive scramble against decay into a predictive, precision-driven science.

What is a “normal” climate? Strategy for adapting to the unknown Andrew Lowe, James Hopeward, Melissa Nursey-Bray | October 28, 2026

https://geneticliteracyproject.org/2026/10/28/what-is-a-normal-climate-strategy-for-adapting-to-the-unknown/ Climate change is worsening. There’s now no chance of holding temperature rise to 1.5°C. The future will bring worsening floods, glacial melt, megafires and lethal heat. But can we call this the “new normal”? The phrase has become common in discussions about the upheavals and damage stemming from human-caused climate change.

ESMO 2026 Less Frequent ICI Therapy Fails in Trial but Offers Lessons (+...)

https://www.medscape.com/index/list_13474_0 Oncology News ESMO 2026 Less Frequent ICI Therapy Fails in Trial but Offers Lessons An immunotherapy de-escalation trial was halted due to a concerning increase in patient deaths. But it also suggests that the approach needs to be better tailored. Medscape Medical News, October 29, 2026

Metabolomics and Nutrition: What Happens to Food Inside the Body

https://www.news-medical.net/health/Metabolomics-and-Nutrition-What-Happens-to-Food-Inside-the-Body.aspx The molecules left behind after a meal offer clues to a central nutrition question: why can the same foods produce different metabolic responses in different people? Metabolomics is the large-scale study of small molecules in a biological system, including those from food and those produced by the body and gut microorganisms. Metabolism comprises the processes by which the body converts food into energy and other molecules needed for growth, repair, and normal function. Distinct metabolomic signatures can help researchers understand how dietary patterns, host genetics, and gut microbial activity influence biological pathways, providing insights beyond traditional nutrition measurements.1–3

Glycation and Aging: How Sugar Damage Affects Skin, Cells, and Health

https://www.news-medical.net/health/Glycation-and-Aging-How-Sugar-Damage-Affects-Skin-Cells-and-Health.aspx What happens when sugars react with the proteins that support your skin and tissues? Scientists are examining the chemistry of glycation and whether changing dietary exposure could influence long-term health. Glycation is a spontaneous, non-enzymatic reaction in which reducing sugars such as glucose and fructose covalently bind to the free amino groups of proteins, lipids, or nucleic acids. This reaction initially results in the formation of unstable Schiff bases that rearrange into more stable early glycation products, including Amadori products derived from glucose and Heyns products derived from fructose, through the Maillard reaction.1 Further structural rearrangements and oxidation can produce advanced glycation end products (AGEs).1

Metaflammation Explained: How Obesity, Diabetes, and Aging Are Connected

https://www.news-medical.net/health/Metaflammation-Explained-How-Obesity-Diabetes-and-Aging-Are-Connected.aspx What happens when expanding fat tissue changes immune activity? Researchers are examining the signals connecting nutrient excess, organ dysfunction, and age-related disease. Obesity, a highly prevalent condition throughout the world, develops through interactions among genetic, environmental, behavioral, and neuroendocrine factors. Sustained nutrient excess can promote adipose tissue expansion by enlarging existing adipocytes and, in some settings, increasing adipocyte number. Dysfunctional expansion can trigger ‘metaflammation,’ a chronic, low-grade inflammatory response associated with metabolic dysfunction.1,3

Sweating the details in exercise oncology The Lancet Oncology (+...)

Sweating the details in exercise oncology The Lancet Oncology https://www.thelancet.com/journals/lanonc/issue/vol27no11/PIIS1470-2045(26)X2010-1

Preparedness for conflict in medical facilities The Lancet Respiratory Medicine (+...)

Preparedness for conflict in medical facilities The Lancet Respiratory Medicine https://www.thelancet.com/journals/lanres/issue/vol14no11/PIIS2213-2600(26)X2010-0

Fiji's national HIV emergency The Lancet HIV (+...)

Fiji's national HIV emergency The Lancet HIV https://www.thelancet.com/journals/lanhiv/issue/vol13no11/PIIS2352-3018(26)X2010-0

Risk of a statistical blind spot: the dangers of data shortages eClinicalMedicine (+...)

Risk of a statistical blind spot: the dangers of data shortages eClinicalMedicine https://www.thelancet.com/journals/eclinm/issue/vol100nonull/PIIS2589-5370(26)X2010-7

Charting New Frontiers in Advanced Breast Cancer: Milestones, Missions, and Mastery Authors: Paolo Tarantino, MD, PhD; Kevin Kalinsky, MD, MS, FASCO; Sibylle Loibl, MD, PhD

https://www.medscape.org/viewarticle/charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7?page=1&uac=148436CN&src=mkmcmr_driv_stan_mscpedu_261028-OUS-HONC-charting-new-frontiers-advanced-breast-cancer-milestones-2026a1000fu7-cta

Future‑Ready Hematologists: Practical and Ethical Use of Artificial Intelligence (AI) in Hematology and Oncology Authors: Jakob N. Kather, MD, MSc; Chan Cheah, MBBS, DMSc; Matthew Lunning, DO, FACP

https://www.medscape.org/viewarticle/1003401?src=mkmcmr_driv_cust_mscpedu_261028-GLOBAL-1003401-cta&uac=148436CN

Mental health disparities among gynecologic cancer survivors: a cross-sectional analysis of the Canadian Longitudinal Study on Aging Melissa Lavecchia1ORCID iD , Alison Shea2,3ORCID iD , Maura Marcucci3,4,5ORCID iD , Parminder Raina3,4ORCID iD , Waldo Jimenez6ORCID iD , Julie M. V. Nguyen (++...)

https://www.academia.edu/2998-7741/3/3/10.20935/AcadOnco8456 Introduction: Mental health outcomes among gynecologic cancer survivors remain under-investigated. Using the Canadian Longitudinal Study on Aging (CLSA), a population-based cohort of over 50,000 individuals, we evaluated differences in mental health outcomes between gynecologic cancer survivors and those without a history of gynecologic cancer. Materials and methods: Cross-sectional data from 26,155 female participants were analyzed. Mental health outcomes included depression (Center for Epidemiologic Studies Depression Scale, CES-D10), psychological distress (Kessler Psychological Distress Scale, K10), and self-rated mental health (SRMH: five-point Likert scale). Regression models were used to describe associations between history of a gynecologic cancer and the three mental health outcomes. Results: Participants with a history of gynecologic cancer (n = 765, weighted prevalence 2.9%, 95% confidence interval (CI) 2.4–3.3) showed a non-significant directional shift toward higher odds of screening positive for depression (adjusted odds ratio (aOR) CES-D10 1.2, 95% CI 0.9–1.5) than those without. However, among participants with any history of cancer, those with a gynecologic cancer were at higher risk of depression (aOR 1.6, 95% CI 1.1–2.5). Among gynecologic cancer survivors, lower household income showed a strong, graded association with all outcomes: income < 20,000 Canadian dollars was associated with elevated odds of depression (odds ratio (OR) 8.4, 95% CI 2.8–25.7), poor SRMH (OR 26.5, 95% CI 4.0–176.2), and psychological distress (OR 22.0, 95% CI 1.3–366.9). Within this group, current smoking was associated with increased odds of depression (OR 4.9, 95% CI 2.5–9.7) and psychological distress (OR 3.6, 95% CI 1.2–10.9). Conclusions: Gynecologic cancer survivors tend to experience a higher burden of depressive symptoms, particularly those facing socioeconomic disadvantage. These findings support routine mental health screening and underscore the need for targeted interventions and sustained psychosocial support throughout treatment and survivorship. https://www.academia.edu/journals/academia-oncology/articles?source=journal-top-nav

Advancing Care in HER2-Mutated NSCLC: Evidence, Diagnostics, and Future Directions Authors: Balazs Halmos, MD, MS

https://www.medscape.org/viewarticle/advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g?page=1&src=mkmcmr_driv_stan_mscpedu_261028-OUS-HONC-advancing-care-her2-mutated-nsclc-evidence-diagnostics-and-2026a1000d6g-cta&uac=148436CN

Accountable Care in 2027: Building the Evidence Base and Driving Practical Policy Solutions (+... +...)

RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations

RISE to the Challenge: Statistical Considerations for Rare Disease Clinical Investigations (+... ... ...) video and more

This public workshop, co-convened by Duke Margolis and the FDA Rare Disease Innovation Hub, will explore statistical considerations in the design, conduct, and analysis of clinical investigations for rare disease medical products. The small patient populations inherent to rare disease present unique challenges that increase the risk of obtaining inconclusive trial results. Addressing these challenges requires careful attention to statistical rigor while utilizing tailored approaches that are necessary to make medical product development feasible in this space. Reliable and timely evidence that relies on data from all available information is critically important to patients and families affected by rare diseases, making the optimization of clinical investigation design, conduct, and analysis a matter of both scientific and ethical urgency. The workshop will focus on key statistical considerations for tailored approaches employed across the full arc of rare disease development programs. Topics will include the role of randomization and blinding, strategies for enhancing efficiency, and factors specific to medical devices. Discussions will explore these statistical considerations with the goal of identifying efficient approaches that maintain scientific rigor and produce meaningful results for rare disease product development. Statistical considerations affect every aspect of drug development, testing, and review, including clinical trial design and measuring product effectiveness; understanding the role of statistical review is important for sponsors, patients, and disease advocates alike. All members of the rare disease community, regardless of prior familiarity with statistical approaches, are encouraged to attend. https://healthpolicy.duke.edu/events/rise-challenge-statistical-considerations-rare-disease-clinical-investigations?utm_medium=email&utm_source=govdelivery Patient Voice in Rare Disease Medical Product Development October 16, 2026 https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/patient-voice-rare-disease-medical-product-development-10162026?utm_medium=email&utm_source=govdelivery FDA Launches the Rare Disease Framework Initiative to Develop a Holistic, Fit-For-Purpose Framework for Rare Disease Drug Development Effort begins by Soliciting Public Feedback https://www.fda.gov/news-events/press-announcements/fda-launches-rare-disease-framework-initiative-develop-holistic-fit-purpose-framework-rare-disease?utm_medium=email&utm_source=govdelivery A New Framework for Rare Disease Review October 2026 https://www.fda.gov/media/195694/download?attachment=&utm_medium=email&utm_source=govdelivery FDA Rare Disease Framework Initiative Public Meeting October 28, 2026 https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fda-rare-disease-framework-initiative-public-meeting-10282026?utm_medium=email&utm_source=govdelivery CDRH Rare Disease Impact Initiative https://www.fda.gov/about-fda/center-devices-and-radiological-health/cdrh-rare-disease-impact-initiative?utm_medium=email&utm_source=govdelivery

FDA Rare Disease Day 2027 March 5, 2027

https://www.fda.gov/news-events/fda-meetings-conferences-and-workshops/fda-rare-disease-day-2027-03052027?utm_medium=email&utm_source=govdelivery

New Pathways in Antithrombotic Therapy Authors: Geoffrey D. Barnes, MD, MSc; Carolyn S. P. Lam, MBBS, PhD; Christian T. Ruff, MD, MPH

https://www.medscape.org/viewarticle/new-pathways-antithrombotic-therapy-2026a1000gtd?page=1&src=mkmcmr_driv_stan_mscpedu_261027-OUS-HONC-new-pathways-antithrombotic-therapy-2026a1000gtd-cta&uac=148436CN

Advancing the DLBCL Paradigm Sequencing Bispecifics in Optimizing Patient Care CME New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT

https://na.eventscloud.com/website/98542/ Join this engaging, interactive symposium exploring the rapidly evolving landscape of bispecific antibodies in diffuse large B-cell lymphoma (DLBCL). Leading international experts will dive into topline clinical evidence across second- and third-line settings and frontline horizons, evaluating pivotal trial data in transplant-ineligible and high-risk populations. Through real-world clinical case scenarios, the panel will debate treatment sequencing—weighing bispecifics against chimeric antigen receptor (CAR) T-cell therapy, individualizing care based on patient fitness and geographic access, and assessing impacts on T-cell fitness. Furthermore, faculty will address key practicalities for integrating bispecific therapies into community practice, from managing safety and treatment logistics to streamlining care coordination and patient pathways. Walk away with concrete solutions to optimize sequencing, safety, and care delivery across the DLBCL continuum. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents With HIV

https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new

From Evidence to Impact: Winning Case Studies from The Lancet–Elsevier Foundation Awards Wednesday, 18/11/2026 · 05:00 Atlantic Time (Canada) (GMT -4:00) Cost: Free

https://www.bigmarker.com/lancet-webinars/from-evidence-to-impact-winning-case-studies-from-the-lancet-elsevier-foundation-awards?utm_bmcr_source=hubspot_email_reg1_lancetelsevierfoundationawards26&_hsmi=446218158&_hsenc=p2ANqtz-_96WygM0EjD8Ov_35nL97V2Z8dan221ZFKebJveTSXmHSi56waQzyfn4wtWBqtis78TMMXZCq6ibXN3_Y1VA7kiDcCBQ&hsCtaAttrib=222131459929 We invite you to our Lancet Webinar, From Evidence to Impact: Winning Case Studies from The Lancet-Elsevier Foundation Awards, on November 18, 2026, at 09:00 GMT/10:00 CET, presented in partnership with The Elsevier Foundation. Attendance is free with registration. Register now Chaired by Zoë Mullan, Editor-in-Chief of The Lancet Global Health, and Maha Rhannam, Elsevier Foundation Partnerships Manager, hear from the three winning teams of the inaugural The Lancet-Elsevier Foundation Evidence to Impact Awards as they share learnings from their award-winning projects, showcasing implementation science in practice from around the world. Although the subject matter and settings are very different, all three demonstrate a deep commitment to community engagement, co-design, evidence-based implementation strategies, and sustainability via long-term partnerships. Hear from the winners: Implementing Essential Emergency and Critical Care in Tanzania Tim Baker, Associate Professor and Critical Care Physician, and Anesthesiologist, Muhimbili University of Health and Allied Sciences, and Karolinska Institutet, Tanzania Karima Khalid, Lecturer and Senior Consultant in Anaesthesia and Critical Care, Muhimbili University of Health and Allied Sciences and Muhimbili Orthopaedic Institute, Tanzania 2YoungLives: Reducing Adolescent Maternal and Perinatal Mortality in Sierra Leone Cristina Fernandez Turienzo, Senior Research Fellow in Maternal, Child and Adolescent health, PI, King’s College London, UK Mangenda Kamara, 2YoungLives Co-Founder and gender expert, University of Sierra Leone & Lifeline Nehemiah Projects, Sierra Leone The ECORRA Trial: Equitable Cancer Outcomes across Rural and Remote Australia Serene Yoong, Associate Professor and Co-Director of the Deakin Centre for Global Preventive Health and Nutrition (GLOBE), Deakin University, Australia Anna Chapman, Senior Research Fellow, Deakin University, Australia You will also have the opportunity to ask your questions during a live Q&A with each of the winning teams. Can't attend the live webinar? By registering you will receive an email with a link to the on-demand version so that you can watch it at your convenience. We hope you can join us for this Lancet Webinar! Yours sincerely, The Lancet Group

PBC push for placebo changes

https://rarerevolutionmagazine.com/pbc-push-for-placebo-changes/ The International PBC Summit puts the discussion of placebo arms in clinical trials high on the agenda The International PBC Summit brings the community together to improve the lives of those with the condition. Discussions at this and previous years’ events have centred on the use of placebo arm trials, the ethics surrounding them and the need for the patient voice to be heard by regulators Written by Karen Roberts, RARE Revolution Interview with Robert Mitchell-Thain, CEO of the PBC Foundation Placebo arms in clinical trials have long been used as a way of measuring the effectiveness of a new medication, but for some primary biliary cholangitis (PBC) patients they can mean lengthy delays to essential treatment. Use of placebo arms in clinical trials has been a persistent concern, with calls for other methods such as the use of real-world evidence (RWE) to be used. It was among the topics discussed at the International PBC Summit 2026. The Summit, held in Edinburgh in April, saw different stakeholders in the PBC community come together to identify unmet needs and discuss solutions.

Single-cell sequencing data shows how pancreatic cancer tumors evolve to resist therapy The multi-omics data on nearly half a million tumor cells showed that even cells with almost identical genetic makeup can show radically different behavior. Written byAllison Whitten, PhD

Single-cell sequencing data shows how pancreatic cancer tumors evolve to resist therapy The multi-omics data on nearly half a million tumor cells showed that even cells with almost identical genetic makeup can show radically different behavior. Written byAllison Whitten, PhD https://www.drugdiscoverynews.com/single-cell-sequencing-data-shows-how-pancreatic-cancer-tumors-evolve-to-resist-therapy-17603 One abnormal cell is all it takes to kickstart cancer development. The cell acquires genetic mutations and then multiplies uncontrollably into clone cells that share nearly identical genes. But, according to new research led by Diane Simeone of University of California, San Diego and Aristotelis Tsirigos’ of New York University. these clone cells don't behave like clones in the very aggressive pancreatic ductal adenocarcinoma (PDAC). In a new paper published in Nature Genetics, the researchers used single-cell RNA sequencing on 443,451 cells taken from 65 PDAC tumors, with 11 tumors that also had matched spatial transcriptomics. Their team showed that the clone cells behaved differently from one another, with some edging out others in their ability to resist treatments and some being more likely to spread and metastasize.

Could PMOS affect the brain? Researchers ​are beginning to uncover differences in brain metabolism and cognitive performance among people with PMOS, but it’s still unknown what drives these changes and whether they have long-term consequences. Written byBree Foster, PhD

Could PMOS affect the brain? Researchers ​are beginning to uncover differences in brain metabolism and cognitive performance among people with PMOS, but it’s still unknown what drives these changes and whether they have long-term consequences. Written byBree Foster, PhD https://www.drugdiscoverynews.com/could-pmos-affect-the-brain-17605 Polycystic ovary syndrome (PCOS), recently renamed polyendocrine metabolic ovarian syndrome (PMOS), is best known for its effects on reproductive health. But the condition extends beyond the ovaries, with metabolic abnormalities such as insulin resistance affecting many people with the syndrome. Now, researchers are investigating whether these abnormalities could also have implications for the brain. A recent study published in the Journal of the Endocrine Society investigated the evidence linking PMOS with cognitive changes and dementia. DDN spoke with Ricardo Azziz, a professor of reproductive endocrinology and gynecology at the University of Alabama at Birmingham and senior author of the study, to understand what the research reveals about the potential relationship between PMOS and brain health, the role insulin resistance might play, and what evidence is needed to determine whether the syndrome affects long-term cognitive function.

From Resection to Dose Individualized Antigen-Directed Therapeutics in Immuno-Oncology CME Phoenix Convention Center Saturday, November 7, 2026 | 12:30 pm - 1:30 pm MT

https://na.eventscloud.com/website/100106/ Messenger RNA (mRNA)-based therapeutics have moved from concept into clinical evaluation across immuno-oncology. This symposium discusses how mRNA-encoded, antigen-directed approaches generate anti-tumor immunity, and how they sit alongside checkpoint inhibition, cell therapy and other novel modalities. Faculty will cover the mechanistic basis of mRNA therapies — antigen selection and prediction, delivery, and the resulting T-cell priming and expansion — and how this differs from other immunotherapeutic approaches. The program will review current clinical evidence across tumor types and disease settings, including earlier-stage and minimal residual disease contexts, matching the strength of each conclusion to the design that produced it. Sessions will also address biomarker and patient-selection considerations, including tumor mutational burden, neoantigen burden and circulating tumor DNA (ctDNA)-based measures, and the multidisciplinary requirements of delivering individualized therapies in practice. The From Resection to Dose: Individualized Antigen-Directed Therapeutics in Immuno-Oncology, content and views expressed therein are those of Medscape Education and not of SITC.

Gene activity in brain diseases mapped

Gene activity in brain diseases mapped At a Glance Scientists constructed an atlas of gene activity in individual brain cells and how it changes in aging, Alzheimer's disease, and other brain diseases. The atlas could provide greater understanding of the biology underlying these diseases and identify potential treatment targets. https://www.nih.gov/news-events/nih-research-matters/gene-activity-brain-diseases-mapped

High metal exposures after wildfires may affect lung function

High metal exposures after wildfires may affect lung function At a Glance After the Maui wildfires, researchers found a link between exposure to higher levels of metal mixtures and worse lung function. This finding suggests the importance of longer-term contaminant testing and health monitoring to assess exposures following wildfires. https://www.nih.gov/news-events/nih-research-matters/high-metal-exposures-after-wildfires-may-affect-lung-function

Speech-based clock captures aging

Speech-based clock captures aging At a Glance Researchers found that many speech features such as pitch, timing, and word choice can help detect accelerated aging and dementia. With further development, this approach could be a less expensive and easier way to measure how aging affects the body and brain. https://www.nih.gov/news-events/nih-research-matters/speech-based-clock-captures-aging

Most Women Take Supplements in Midlife, so Doctors Should Ask About Them Sony Salzman

https://www.medscape.com/viewarticle/most-women-take-supplements-midlife-so-doctors-should-ask-2026a10014bf?ecd=WNL_trdalrt_pos1_ous_261028_etid8841063&uac=148436CN&impID=8841063 https://www.medscape.com/viewarticle/most-women-take-supplements-midlife-so-doctors-should-ask-2026a10014bf?ecd=WNL_trdalrt_pos1_ous_261028_etid8841063&uac=148436CN&impID=8841063#:~:text=Supplements%20are%20a,Annual%20Meeting.

The New Era of mHSPC Treatment: Evaluating Emerging Doublet and Triplet Combinations Authors: Neal D. Shore, MD, FACS; Sarah Caulfield, PharmD, BCOP; Rana R. McKay, MD, FASCO

https://www.medscape.org/viewarticle/new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7?page=1&src=mkmcmr_driv_stan_mscpedu_261028-OUS-HONC-new-era-mhspc-treatment-evaluating-emerging-doublet-and-2026a1000kt7-cta&uac=148436CN

Clinical Turning Points Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT

Clinical Turning Points Decisions That Shape Care Across the Spectrum of Systemic Mastocytosis CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT https://na.eventscloud.com/website/98569/ Systemic mastocytosis (SM) is a rare hematologic disorder that often presents with a wide variety of nonspecific symptoms. Despite advances in the diagnosis and growing awareness of SM, the full patient burden of nonadvanced SM (nonAdvSM) remains underrecognized and underaddressed in clinical practice. Join us for this interactive 90-minute CME/CE symposium featuring livestreaming and social media simulcast. Expert faculty will examine critical clinical turning points to overcome inertia and uncertainty, optimizing treatment decisions—particularly when considering escalation to disease-directed therapy. Walk away with practical strategies to evaluate disease control, integrate emerging clinical evidence, and optimize management across the SM continuum. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

Miv-cel Shows Durable Results in Stiff Person Syndrome and Myasthenia Gravis

Naji Gehchan, MD, MBA, Chief Medical and Development Officer at Kyverna Therapeutics, discusses one-year data showing sustained benefits of KYV-101 (mivocabtagene autoleucel ; Miv-cel) in stiff person syndrome (SPS), along with longer-term follow-up data in generalized myasthenia gravis (gMG). SPS and gMG are rare neurological and neuromuscular disorders: SPS: SPS is a rare, progressive neurological autoimmune disease that causes muscle stiffness and painful spasms that can affect walking and mobility. Up to 80% of patients lose their mobility over time, and there are currently no FDA-approved treatments. gMG: gMG is a rare autoimmune neuromuscular disease characterized by muscle weakness and fatigue. As the disease progresses, it can interfere with daily activities, such as speaking, chewing, swallowing, and breathing. Positive one-year topline data from the KYSA-8 clinical trial (NCT06588491) were announced on September 24, 2026. KYSA-8 was a registrational, phase two, open-label, single-arm, multicenter study of miv-cel. Miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy with CD28 co-stimulation. It’s designed to achieve deep B-cell depletion, reset the immune system, and deliver durable drug-free, disease-free remission in autoimmune diseases with a single dose. A total of 26 adult patients who had an inadequate response to at least one immunotherapy treatment participated in the study. Each participant received a single dose of miv-cel. Among patients who achieved a clinically meaningful improvement in the timed 25-foot walk at primary analysis, 95% maintained that benefit at 12 months. Of the 12 patients who needed a walking aid before treatment, 67% still did not require assistance at the 12-month follow-up. Furthermore, 92% of patients remained off chronic immunotherapies for SPS. Also announced were longer-term follow-up data for its KYSA-6 trial (NCT06193889). KYSA-6 is a phase 2/3 trial evaluating miv-cel, administered as a single dose, in patients with gMG. A total of seven adult patients participated in the study. Follow-up now extends to one year and beyond (up to 1.5 years) in five patients, with one patient at 9 months and another at 6 months. All seven participants achieved clinically meaningful improvements in both the Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scores at 24 weeks, while all five participants with at least one year of follow-up maintained clinically meaningful improvements. Additionally, six of the seven patients remained off immunosuppressant therapies at their latest follow-up. Miv-cel continued to be well-tolerated in both studies. In the KYSA-8 trial, no high-grade cases of cytokine release syndrome (CRS) or immune effector cell-associated neurotoxicity syndrome (ICANS) and no cases of immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) were reported through the 12-month follow-up. In the KYSA-6 trial, no high-grade CRS, no ICANS, and no cases of IEC-HS were reported during the available follow-up.

Clinical Trials for Rare Endocrine Disorders

In this episode, endocrinologist Margarita Ochoa-Maya, MD, speaks with endocrinologist Katherine Arakay, MD, of the University of California, Los Angeles (UCLA), about clinical trials for rare endocrine disorders. The conversation examines clinical trials from three perspectives: patients, clinical researchers, and sponsors.

Clinical Trials for Rare Endocrine Disorders | Rare Endocrine Exchange by CheckRare Staff| Published on: Oct 28, 2026

Clinical Trials for Rare Endocrine Disorders | Rare Endocrine Exchange by CheckRare Staff| Published on: Oct 28, 2026 In this episode, endocrinologist Margarita Ochoa-Maya, MD, speaks with endocrinologist Katherine Arakay, MD, of the University of California, Los Angeles (UCLA), about clinical trials for rare endocrine disorders. The conversation examines clinical trials from three perspectives: patients, clinical researchers, and sponsors. https://checkrare.com/clinical-trials-for-rare-endocrine-disorders-rare-endocrine-exchange/

Do Italian Women Really Have Fewer Mammograms? Roberta Villa, MD

https://www.medscape.com/viewarticle/do-italian-women-really-have-fewer-mammograms-2026a10014j1?src= Sometimes data seem straightforward but can be misleading. I am referring to the data recently published by Eurostat on the availability of equipment and women’s participation in mammography screening within the target age group. According to the bar chart comparing screening rates in 2019 with those in 2024 across EU countries (plus Switzerland, Iceland, and Norway), Italy shows a sharp decline. This negative trend is shared by ten other countries, including Netherlands, France, Ireland, and especially Malta, where the decline can be described as a veritable collapse — from a rate nearing 70% in 2019 to less than 50% in 2024.

6 New GI Studies That Could Shift IBD Care and Colorectal Cancer Screening American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting Highlights: Part 2 David A. Johnson, MD

https://www.medscape.com/viewarticle/6-new-gi-studies-could-shift-ibd-care-and-colorectal-cancer-2026a10013vj?src=

FDA Expands Talazoparib Combo Indication in Prostate Cancer Amy Norton

https://www.medscape.com/viewarticle/fda-expands-talazoparib-combo-indication-prostate-cancer-2026a10014gv?src= The FDA has approved the PARP inhibitor talazoparib (Talzenna, Pfizer) in combination with enzalutamide for the treatment of patients with metastatic androgen pathway modulation-naive or -sensitive (mAPMN/S) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test. The regimen was first approved by the FDA in 2023, for patients with HRR gene-mutated metastatic castration-resistant prostate cancer.

The Surprising Clues BMI May Miss in Head and Neck Cancer Lisa O’Mary

https://www.medscape.com/viewarticle/surprising-clues-bmi-may-miss-head-and-neck-cancer-2026a10014h5 A recent retrospective cohort study suggested that higher BMI might be associated with improved overall survival in patients with head and neck cancers receiving radiation therapy. These findings reflect what’s known as the obesity paradox — the observation that individuals with cancer or other diseases who have overweight or obesity may actually have lower mortality rates.

Divarasib Beats Approved KRAS Inhibitors in Lung Cancer Frederik Joelving

https://www.medscape.com/viewarticle/divarasib-beats-approved-kras-inhibitors-lung-cancer-2026a10014jm?src= The investigational targeted therapy divarasib extends overall survival in patients with previously treated, advanced KRAS G12C-mutated non-small cell lung cancer (NSCLC), outperforming two existing KRAS inhibitors, according to findings from the phase 3 Krascendo 1 trial.

Dual Knockdown CAR T-Cell Therapy Linked to High Response Rates in R/R LBCL

https://www.medscape.com/viewarticle/dual-knockdown-car-t-cell-therapy-linked-high-response-rates-2026a10014jf?src= Anbalcabtagene autoleucel (anbal-cel), a CD19-directed chimeric antigen receptor (CAR) T-cell therapy with dual PD-1 and T-cell immunoreceptor with immunoglobulin and immunoreceptor tyrosine-based inhibitory motif domains (TIGIT) knockdown was associated with high response rates in patients with relapsed or refractory large B-cell lymphoma (LBCL) in a phase 1/2 study. Among 73 evaluable patients, the complete response rate was 67.1%, and those who maintained complete response for at least 6 months had 18-month progression-free survival (PFS) and overall survival (OS) rates of 79.4% and 83.9%, respectively.

Editorial p1193 Microplastics and cancer: a looming threat? The Lancet Oncology (+...)

Editorial p1193 Microplastics and cancer: a looming threat? The Lancet Oncology https://www.thelancet.com/journals/lanonc/issue/vol27no10/PIIS1470-2045(26)X2009-5

Editorial p1341 Sweating the details in exercise oncology The Lancet Oncology (+...)

Editorial p1341 Sweating the details in exercise oncology The Lancet Oncology https://www.thelancet.com/journals/lanonc/issue/vol27no11/PIIS1470-2045(26)X2010-1

Read our ESMO Congress 2026 content (+++++)

ARTICLES Ruzaltatug rezetecan versus chemotherapy for EGFR-mutated advanced non-small-cell lung cancer progressing after EGFR tyrosine kinase inhibitor therapy (HERON-Lung01): interim analysis of a randomised, open label, phase 3 trial in China Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01899-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz-8PatPY-q5syDq5cRIEaodGLPJl6YwK3bAMIaCb30AjmF6TcS3uAY2RLxyx8U7acXNOZzFE0nVCKpkYgrnR9snyjL1uIw&_hsmi=445989026&utm_content=445989026&utm_source=hs_email 14-day versus 28-day trifluridine–tipiracil plus bevacizumab for refractory metastatic colorectal cancer (PRABITAS): a pragmatic, multicentre, open-label, randomised, phase 3, non-inferiority trial in Japan Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)01782-4/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz-_nIKpAwhV594yXgYYzY64WirU0zr_AxExT1vjUqR094_ebIUZUAxRn4M40OGF3ZGobOI77gyMwVKOM9_HrJ7Egfj4RBg&_hsmi=445989026&utm_content=445989026&utm_source=hs_email Izalontamab brengitecan versus platinum-based chemotherapy in EGFR-mutated advanced non-squamous non-small-cell lung cancer after progression on third generation EGFR tyrosine kinase inhibitors (PANKU-Lung01): a multicentre, randomised, open-label, phase 3 trial in China Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(26)02026-X/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz--4WcK9QQqJxacnaGsorwRDGMTkmbA_t_cDgRH-3ws5M_ec5vg-vDrnyMFxA-oHChkvaKOu9547FfxzTB6koT762wa-Ng&_hsmi=445989026&utm_content=445989026&utm_source=hs_email Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial Free with registration until Nov 4, 2026 https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00446-8/abstract?utm_campaign=conferencealerts&utm_medium=email&dgcid=hubspot_email_conferencealerts_esmo26&_hsenc=p2ANqtz-9CMdTnEx56qrqktZWxDpyFMzdjXsigEZnhqtw3f8p0Z5d8OjvqQ2eZyn71nJ8Pu3_zXySq8QBDZkXpufSRovTsAic70w&_hsmi=445989026&utm_content=445989026&utm_source=hs_email An integrated lifestyle intervention for mitigation of adverse effects associated with androgen deprivation therapy for prostate cancer (STAMINA): a multicentre, randomised trial Open Access https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(26)00304-9/fulltext?dgcid=hubspot_email_conferencealerts_esmo26&utm_campaign=conferencealerts&utm_medium=email&_hsenc=p2ANqtz-_8_vinwlzYx-4XETdJE5x1KfLxIUjXo7MgrvAQo1VfUyuZ9exbcO_JikI8XwCXpnIIWIaJcMRIas7YlxToAghQI0nk7Q&_hsmi=445989026&utm_content=445989026&utm_source=hs_email

Immunotherapy Combo Improves Bladder Cancer Event-Free Survival Tara Haelle

https://www.medscape.com/viewarticle/immunotherapy-combo-improves-bladder-cancer-event-free-2026a100148s?ecd=WNL_trdalrt_pos1_ous_261027_etid8837163&uac=148436CN&impID=8837163 Patients with muscle-invasive bladder cancer who received neoadjuvant and adjuvant durvalumab and neoadjuvant enfortumab vedotin with radical cystectomy, with or without peri- and postoperative tremelimumab, had significantly better event-free survival than those who underwent surgery alone.

Acknowledging the Rare Navigating Diagnostic and Therapeutic Complexities in Rare Hematologic Disorders CME/CNE/CPE New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 3:30 pm - 5:00 pm CT

https://na.eventscloud.com/website/98255/ This live, case-based symposium is designed to help healthcare professionals interpret and apply clinically relevant evidence to individualized treatment decisions for persons with hemophilia. The program will focus on persistent disease and treatment burden despite improved outcomes, the need to evaluate treatment success beyond bleeding rates, and the importance of tailoring care to patient-specific factors that drive burden across subgroups, including emerging data on nonfactor replacement prophylaxis options. Through expert-led discussion of real-world cases and audience polling, participants will examine how the expanding availability of novel prophylactic options—including factor replacement therapies, factor VIIIa mimetics, rebalancing agents, and gene therapies—offer new strategies for optimizing not only bleed rates but long-term joint health, treatment burden, and quality of life for people with hemophilia. Friday Satellite Symposium on Hematology, preceding the 68th ASH Annual Meeting and Exposition

Unifying Expertise in IDH-Mutant Glioma Care: A Multidisciplinary Dialogue in the Oncology Team Authors: Shawn Hervey-Jumper, MD; Markus Bredel, MD, PhD; Matthias Preusser, MD

https://www.medscape.org/viewarticle/unifying-expertise-idh-mutant-glioma-care-multidisciplinary-2026a1000myk?page=1&src=mkmcmr_driv_stan_mscpedu_261027-OUS-HONC-unifying-expertise-idh-mutant-glioma-care-multidisciplinary-2026a1000myk-cta&uac=148436CN

Lipoprotein(a) Management Simplified Source: National Lipid Association (++++++) (+++)

Lipoprotein(a) Management Simplified Source: National Lipid Association https://reference.medscape.com/cc2/p10/lipoprotein-management-simplified-guideline-nla-2026a10010dl?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Staphylococcus Aureus Bacteremia Source: Infectious Diseases Society of America, European Society of Clinical Microbiology and Infectious Diseases https://reference.medscape.com/cc2/p10/idsa-escmid-staphylococcus-aureus-bacteremia-guideline-2026a1000y7s?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Management of Rosacea Source: American Acne & Rosacea Society https://reference.medscape.com/cc2/p10/aars-management-rosacea-guideline-2026a1000ye4?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Diagnosis and Management of Chronic Complex Regional Pain Syndrome Types I and II Source: American Society of Interventional Pain Physicians https://reference.medscape.com/cc2/p10/asipp-chronic-complex-regional-pain-guideline-2026a10011i4?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Management of Type 2 Diabetes Source: American Diabetes Association, European Association for the Study of Diabetes https://reference.medscape.com/cc2/p10/management-type-2-diabetes-ada-easd-guidelines-2026a100112t?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Vaccination During Pregnancy and the Postpartum Period Source: American College of Obstetricians & Gynecologists https://reference.medscape.com/cc2/p10/acog-vaccination-during-pregnancy-and-postpartum-guideline-2026a10012am?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Urological Infections Source: European Association of Urology https://reference.medscape.com/cc2/p10/eau-guidelines-urological-infections-2023a1000eta?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer Source: American Society of Clinical Oncology; Medically Reviewed by Professor Maurie Markman https://reference.medscape.com/cc2/p10/asco-guideline-advanced-gastroesophageal-cancer-2026a1000wrv?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614 Subclinical Hypothyroidism in Primary Care Dr Kevin Fernando https://reference.medscape.com/cc3/p10/subclinical-hypothyroidism-2023a1000csa?ecd=mkm_ret_261027_mscpmrk-OUS_InFocus_etid8824614&uac=148436CN&impID=8824614

C3G and the Pediatric VALIANT Study (30 videos) FDA Approvals and Regulations | Rare Discussions

Z-Basivarsen Shows Functional Improvements in One-Year Data for Myotonic Dystrophy Type 1 (49 videos) Treatments | Rare Discussions

Efficacy of Infigratinib on Achondroplasia

Using Artificial Intelligence To Reduce Diagnostic Delays

FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic Syndrome by Chad Birt| Published on: Oct 26, 2026

FDA Approves Gazyva to Reduce Relapse Risk in Patients With Idiopathic Nephrotic Syndrome by Chad Birt| Published on: Oct 26, 2026 Andrea Callaway, president and founder of The Nephrotic Syndrome Foundation, discusses the FDA approval of Gazyva (obinutuzumab) for idiopathic nephrotic syndrome (INS) and what the approval means for affected families. https://checkrare.com/fda-approves-gazyva-to-reduce-relapse-risk-in-patients-with-idiopathic-nephrotic-syndrome/

New Formulation of Berotralstat Approved for Adults and Adolescents With Hereditary Angioedema by Madaline Spencer| Published on: Oct 26, 2026

https://checkrare.com/new-formulation-of-berotralstat-approved-for-adults-and-adolescents-with-hereditary-angioedema/ The US Food and Drug Administration (FDA) has approved the oral pellet formulation of once-daily Orladeyo (berotralstat) for prophylactic therapy in patients ages 12 years and older with hereditary angioedema (HAE). HAE is a rare condition characterized by recurrent episodes of severe swelling of the skin and mucous membranes. These attacks generally become more frequent after puberty, and continue throughout life, often affecting the skin, gastrointestinal tract, and upper airway. Triggers for these episodic HAE attacks vary but may include emotional and physical stressors, including dental procedures. HAE may be caused by genetic changes in the SERPING1 gene (also called the C1NH gene) or in the F12 gene. In some cases, the genetic cause is not yet certain.

Z-Basivarsen Shows Functional Improvements in One-Year Data for Myotonic Dystrophy Type 1 by Chad Birt| Published on: Oct 27, 2026

Z-Basivarsen Shows Functional Improvements in One-Year Data for Myotonic Dystrophy Type 1 by Chad Birt| Published on: Oct 27, 2026 Laurie Gutmann, MD, professor of neurology at Indiana University, discusses data showing functional improvements with zeleciment basivarsen (z-basivarsen; DYNE-101) in patients with myotonic dystrophy type 1. https://checkrare.com/z-basivarsen-shows-functional-improvements-in-one-year-data-for-myotonic-dystrophy-type-1/

Actionable Approaches to AL Amyloidosis Care Diagnosing Earlier, Treating Smarter, Managing Together CME New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 11:30 am - 1:00 pm CT

https://na.eventscloud.com/website/98321/ In this 90-minute symposium, some of the foremost experts in light-chain (AL) amyloidosis research and care will share actionable strategies for navigating complex challenges in this rare disease. Topics will include Diagnosis, staging, and stratifying: Improving timeliness and accuracy Treatment: Developing personalized, evidence-based plans Patient support: Helping patients navigate the long journey Workflows: Optimizing systems and teamwork The event speakers, involved in some of the most consequential trials in AL amyloidosis, will also examine key data for current treatments and novel approaches like fibril targeting. Register now to secure your spot, and prepare your questions for the live Q&A at the end of the session.

Antibody-Drug Conjugate Therapy for Early Breast Cancer: Innovations That Shape the Future of Care Authors: Sibylle Loibl, MD, PhD; Javier Cortés, MD, PhD; Icro Meattini, MD

https://www.medscape.org/viewarticle/antibody-drug-conjugate-therapy-early-breast-cancer-2026a10010lp?page=1&src=mkmcmr_driv_32025_mscpedu_451770.25_ace_launch

American College of Chest Physicians (CHEST) 2026 Annual Meeting

https://www.medscape.com/c25/p14/american-college-chest-physicians-chest-2026-annual-meeting-2026a1000zqc

Secrets of Successful CTEPH Management Heidi Splete

https://www.medscape.com/viewarticle/secrets-successful-cteph-management-2026a100142t?ecd=wnl_tp10_daily_261025_MSCPEDIT_etid8825125&uac=148436CN&impID=8825125 Synthesizing medical management strategies with surgical and interventional treatments improves outcomes in patients with chronic thromboembolic pulmonary hypertension (CTEPH), said Anjali Vaidya, MD, FACC, FASE, in a presentation at the American College of Chest Physicians (CHEST) 2026 Annual Meeting. However, diagnosis comes first, and CTEPH is not only rare but can mimic many other conditions, leading to diagnostic delays, said Vaidya, professor of medicine and director of the Advanced Pulmonary Hypertension Program at Lewis Katz School of Medicine, Temple University in Philadelphia.

Depression, Not Anxiety, Linked to Poorer Cognition After Stroke

https://www.medscape.com/viewarticle/depression-not-anxiety-linked-poorer-cognition-after-stroke-2026a10013i3?ecd=wnl_tp10_daily_261025_MSCPEDIT_etid8825125&uac=148436CN&impID=8825125 Depression, but not anxiety, was independently linked to poorer executive function over 5 years after ischaemic stroke. The association between depression and visuospatial function was less robust. Anxiety was present in 27%-36% of patients at each assessment.

Can Transcatheter Aortic Valves in Mitral Position Work for Inoperable Patients?

https://www.medscape.com/viewarticle/can-transcatheter-aortic-valves-mitral-position-work-2026a1001420?ecd=wnl_tp10_daily_261025_MSCPEDIT_etid8825125&uac=148436CN&impID=8825125 In patients considered too high risk for a redo surgery, placing a transcatheter aortic valve inside a failed mitral valve (valve-in-valve) demonstrated a high rate of technical success and a low rate of in-hospital mortality, with symptoms improving during follow-up.